6Chang L Y, Hsiung C A, Lu C A, et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71 [ J ]. Pediatr Res, 2006, 60 (4) : 466 - 471.
7Lin Y W, Chang K C, Kao C M, et al. Lymphocyte and antibody re- sponses reduce enterovirus 71 lethality in mice by decreasing tissue vi- ral loads[ J ]. J Virol, 2009, 83 ( 13 ) : 6477 - 6483.
8Wang S M, Lei H Y, Huang K J, et al. Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients : roles of cytokines and cel- lular immune activation in patients with pulmonary edema [ J ]. J Infect Dis, 2003, 188(4) : 564 -570.
6Chang LY. Enterovirus 71 in Taiwan. Pediatr Neonatol,2008,49 : 103-112.
7Cho HK, Lee NY, Lee H. Enterovirus 71-associated hand, foot and mouth diseases with neurologic symptoms, a university hospital experience in Korea, 2009. Korean J Pediatr,2010,53:639-643.
8Koroleva GA, Lukashev AN, Khudiakova LV. Encephalomyelitis caused by enterovirus type 71 in children. Vopr Virusol,2010,55 : 4-10.
9Chang LY, Lee CY, Kao CL. Hand, foot and mouth disease complicated with central nervous system involvement in Taiwan in 1950-1951 . J Formos Med Assoc,2007,106 : 173-176.
10Wintergerst KA, Buckingham B, Gandrud L, et al. Association of hypoglycemia, hyperglycemia, and glucose variability with morbidity and death in the pediatric intensive care unit. Pediatrics,2006, 118 : 173-179.
3Cai Y, Ku Z, Liu Q et al. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. [ J ]. Vaccine. 2014, 32 (21) :2406-2412.
4H T, QZ Y,J Let al. Clinical Features and Management Outcomes of Severe Hand, Foot and Mouth Disease[ J]. Med Princ Pract. 2012 ;21 (4) :355-359.
